Archive: Company News
BellaSeno Presents Novel Production Workflow for Customized, 3D-Printed Bone Scaffolds
— Presentation at the German Congress of Orthopaedics and Traumatology (DKOU)
— Treatment of large segmental bone defects with resorbable scaffolds
— Leading-edge workflow for the design and manufacturing of customized bone scaffolds
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that the Company has presented novel data on the design and manufacturing of customized, 3D-printed bone scaffolds at the recent German Congress of Orthopaedics and Traumatology (DKOU).
MetrioPharm Receives Rare Pediatric Disease Designation (RPDD) for MP1032 from the U.S. FDA
— FDA grants RPDD for the treatment of Duchenne muscular dystrophy (DMD)
— MetrioPharm may be eligible for a priority review voucher with a market value in excess of USD 100 million
— MetrioPharm has recently raised CHF 18 million for the development of MP1032 in DMD in a Series D round and is targeting a second closing
MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for MP1032 for the treatment of Duchenne muscular dystrophy.
ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
— Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumors
— Trial overview presented at ESMO Congress 2023 (Madrid, Spain)
— Dose levels 1 and 2 successfully completed
ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, today announced an update on the ongoing Phase 1a/b trial of its lead program IOS-1002 in Australia. The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
– Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors
Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 17, 2023 – ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, today announced a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its lead compound IOS-1002 in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in an ongoing Phase 1a/b clinical trial for the treatment of patients with advanced solid tumors.